biostudies-arrayexpressUnknownTranscriptomicsGenomicsProteomicsDr Rupesh DashIllumina NovaSeq 6000RNA-seq of coding RNAHomo sapiensHomo sapienshttps://www.ebi.ac.uk/biostudies/studies/E-MTAB-15141This study employs single-cell sequencing to identify rare, transient cisplatin-resistant subpopulations in OSCC, analyzing their gene expression and signaling pathways. By targeting these vulnerable cell states, we aim to develop combination therapies that prevent resistance emergence, enhancing cisplatin’s effectiveness and overcoming treatment failure in oral squamous cell carcinoma.biostudies-arrayexpressSample Collection - SCC9 CisR WT and BASP1 KD cells were cultured in cell culture conditions in DMEM-F12 (10%FBS) . Cells were trypsinized and subjected to RNA isolation.Nucleic Acid Extraction - Total RNA was isolated using Direct-Zol RNA miniprep (R2052) RNA isolation kit.Sequencing - Library cDNAs were sequenced in NovaSeq 6000 Sequencing SystemLibrary Construction - To prepare an RNA-Sequencing library, 500ng of total RNA was used to isolate mRNA using magnetic beads (PolyA mRNA Isolation Module, NEB Cat No# E7490L). The RNA-Seq library was then prepared using an mRNA library preparation kit (NEB Cat No# E7770L) strictly following the vendor’s recommended protocol. Following library preparation, the library concentration was measured using Qubit 2.0 (Invitrogen), and the appropriate fragmentation sizes were confirmed using Bio-analyzer (Agilent Cat No# 5067-5582).OrganizationMINSEQE ScoreAssays and DataMAGE-TAB FilesDr Rupesh DashfalseBASP1 drives cisplatin resistance through LIN7A mediated epithelial-mesenchymal transition in OSCC. Bulk RNA seqThis study employs single-cell sequencing to identify rare, transient cisplatin-resistant subpopulations in OSCC, analyzing their gene expression and signaling pathways. By targeting these vulnerable cell states, we aim to develop combination therapies that prevent resistance emergence, enhancing cisplatin’s effectiveness and overcoming treatment failure in oral squamous cell carcinoma.2026-02-02T00:00:00Z2026-02-02T05:18:54.198Z2025-05-19T09:43:35.647ZE-MTAB-15141ERP172706EFO_0002944EFO_0004170EFO_0005518EFO_0003738EFO_0004184